Everything you need to know before investing in PAR and CUV during the coronavirus.

Are you frustrated with the market acting like a rollercoaster? If yes, then you are not alone. Many smart investors, have had enough with the media suffocating the public on the coronavirus. Many investors are now basing their entire financial decision on what the media reports. Consequently, the coronavirus fear is beating down fundamentally strong […]

Here’s why PAR is worth watching now more than ever?

When thinking of a biotech market mover Paradigm Biopharmaceuticals (ASX: PAR) instantly comes to mind. Paradigm, through its repurposed drug Zilosul, aims to alleviate the suffering and cartilage degradation of Osteoarthritis. PAR’s impressive clinical developments in osteoarthritis and 240% surge in 2019 captivated both the scientific and investment world. Paradigm kickstarted 2020 off with a […]

Will PAR’s H1 2020 financials trigger a surge this week?

In my opinion, biotechnology is the most entertaining industry in the stock market. Why? Three reasons.   1) Biotech tends to be up even when the market is down. Because our ageing population continues to demand the best medicine to sustain a higher life expectancy. 2) Second, there is a range of top-quality biotechs under […]

Paradigm Bio-Pharmaceutical (ASX) with major stock movement- how long will it hold ?

Before I start, I am obliged to remind our viewers that this is not advice only general commentary from my extensive research in this area. Since launching , YIG has published articles relating to commodities (Cobalt) and Tech companies. Now, YIG has a new and exciting list of companies that will be assessed, to give […]